44 related articles for article (PubMed ID: 20146435)
1. Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors.
Niu P; Tao Y; Lin G; Xu H; Meng Q; Yang K; Huang W; Song M; Ding K; Ma D; Fan M
J Med Chem; 2024 Apr; 67(8):6099-6118. PubMed ID: 38586950
[TBL] [Abstract][Full Text] [Related]
2. Discovery of macrocyclic CDK2/4/6 inhibitors with improved potency and DMPK properties through a highly efficient macrocyclic drug design platform.
Meng F; Liu J; Cao Z; Yu J; Steurer B; Yang Y; Wang Y; Cai X; Zhang M; Ren F; Aliper A; Ding X; Zhavoronkov A
Bioorg Chem; 2024 May; 146():107285. PubMed ID: 38547721
[TBL] [Abstract][Full Text] [Related]
3. Applications of palladium-catalyzed C-N cross-coupling reactions in pharmaceutical compounds.
Emadi R; Bahrami Nekoo A; Molaverdi F; Khorsandi Z; Sheibani R; Sadeghi-Aliabadi H
RSC Adv; 2023 Jun; 13(27):18715-18733. PubMed ID: 37346956
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, Antibacterial, and Antioxidant Evaluation of Novel Series of Condensed Thiazoloquinazoline with Pyrido, Pyrano, and Benzol Moieties as Five- and Six-Membered Heterocycle Derivatives.
Saleh EAM; Al Dawsari AM; Husain K; Kutty IH; Rai KML
Molecules; 2021 Jan; 26(2):. PubMed ID: 33445580
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.
Whittaker SR; Barlow C; Martin MP; Mancusi C; Wagner S; Self A; Barrie E; Te Poele R; Sharp S; Brown N; Wilson S; Jackson W; Fischer PM; Clarke PA; Walton MI; McDonald E; Blagg J; Noble M; Garrett MD; Workman P
Mol Oncol; 2018 Mar; 12(3):287-304. PubMed ID: 29063678
[TBL] [Abstract][Full Text] [Related]
6. Applications of Palladium-Catalyzed C-N Cross-Coupling Reactions.
Ruiz-Castillo P; Buchwald SL
Chem Rev; 2016 Oct; 116(19):12564-12649. PubMed ID: 27689804
[TBL] [Abstract][Full Text] [Related]
7. Facile synthesis and biological assays of novel 2,4-disubstituted hydrazinyl-thiazoles analogs.
Ghanbari Pirbasti F; Mahmoodi NO
Mol Divers; 2016 May; 20(2):497-506. PubMed ID: 26754629
[TBL] [Abstract][Full Text] [Related]
8. Organocatalysis in heterocyclic synthesis: DABCO as a mild and efficient catalytic system for the synthesis of a novel class of quinazoline, thiazolo [3,2-a]quinazoline and thiazolo[2,3-b] quinazoline derivatives.
Behbehani H; Ibrahim HM
Chem Cent J; 2013 May; 7(1):82. PubMed ID: 23651877
[TBL] [Abstract][Full Text] [Related]
9. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Hole AJ; Baumli S; Shao H; Shi S; Huang S; Pepper C; Fischer PM; Wang S; Endicott JA; Noble ME
J Med Chem; 2013 Feb; 56(3):660-70. PubMed ID: 23252711
[TBL] [Abstract][Full Text] [Related]
10. Free enthalpies of replacing water molecules in protein binding pockets.
Riniker S; Barandun LJ; Diederich F; Krämer O; Steffen A; van Gunsteren WF
J Comput Aided Mol Des; 2012 Dec; 26(12):1293-309. PubMed ID: 23247390
[TBL] [Abstract][Full Text] [Related]
11. Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors.
Dobeš P; Fanfrlík J; Rezáč J; Otyepka M; Hobza P
J Comput Aided Mol Des; 2011 Mar; 25(3):223-35. PubMed ID: 21286784
[TBL] [Abstract][Full Text] [Related]
12. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.
Wang S; Meades C; Wood G; Osnowski A; Anderson S; Yuill R; Thomas M; Mezna M; Jackson W; Midgley C; Griffiths G; Fleming I; Green S; McNae I; Wu SY; McInnes C; Zheleva D; Walkinshaw MD; Fischer PM
J Med Chem; 2004 Mar; 47(7):1662-75. PubMed ID: 15027857
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2.
Horiuchi T; Nagata M; Kitagawa M; Akahane K; Uoto K
Bioorg Med Chem; 2009 Dec; 17(23):7850-60. PubMed ID: 19889545
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.
Misra RN; Xiao HY; Williams DK; Kim KS; Lu S; Keller KA; Mulheron JG; Batorsky R; Tokarski JS; Sack JS; Kimball SD; Lee FY; Webster KR
Bioorg Med Chem Lett; 2004 Jun; 14(11):2973-7. PubMed ID: 15125971
[TBL] [Abstract][Full Text] [Related]
15. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
16. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.
McIntyre NA; McInnes C; Griffiths G; Barnett AL; Kontopidis G; Slawin AM; Jackson W; Thomas M; Zheleva DI; Wang S; Blake DG; Westwood NJ; Fischer PM
J Med Chem; 2010 Mar; 53(5):2136-45. PubMed ID: 20146435
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
